Epidemiology of Non-Hodgkin's Lymphoma in India

被引:66
作者
Nair, Reena [1 ]
Arora, Neeraj [1 ]
Mallath, Mohandas K. [1 ]
机构
[1] Tata Med Ctr, Dept Clin Hematol, Kolkata 700156, India
关键词
Non-Hodgkin's lymphoma; Immune phenotype; Anti-CD20; antibody; Survival; Time trends; Cancer registry; HEMATOPOIETIC MALIGNANCIES; SOUTH-INDIA; RISK; CLASSIFICATION; MORTALITY; NEOPLASMS; PATTERNS;
D O I
10.1159/000447577
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-Hodgkin's lymphoma (NHL) is a common hematological malignancy. The age-adjusted incidence rates for NHL in men and women in India are 2.9/100,000 and 1.5/100,000, respectively. These are about one fourth of the incidence rates reported from Western Europe or North America. Within India, the incidence is several-fold higher in urban cancer registries compared to rural areas; the incidence being higher in metropolitan cities and Indian immigrants suggesting that urban lifestyles and economic progress may increase the cancer incidence. Compared to developed nations, the key differences in the presentation in India include: median age of 54 years (almost a decade less), higher male to female ratio, higher proportion of patients with B-symptoms (40-60 vs. 20-30%), poor ECOG performance status (>= 2) at diagnosis (50 vs. 20-30%), higher frequency of diffuse large B-cell lymphomas (60-70 vs. <40%), lower frequency of follicular NHL (<20 vs. 30-40%) and T-cell type in 10-20 vs. <10%. The estimated mortality rate due to NHL is higher in India than in North America and Western Europe. Diagnostic and treatment delays, incorrect diagnosis and inappropriate or sub-optimal treatment may be possible reasons for the poor outcome. Any improvement in the outcomes for NHL in India will require a nationwide approach, e.g. creation of several regional and district-level centers with expertise in lymphoma management. Collection of data on patient- and disease-related characteristics, treatment outcome, development of infrastructure, centralized review of histopathology subtype, novel treatment protocols, rigorous follow-up, training of staff, and financial support towards treatment could be possible strategies to improve the outcome. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:18 / 25
页数:8
相关论文
共 31 条
  • [1] Smoking and the risk of leukemia, lymphoma, and multiple myeloma (Sweden)
    Adami, J
    Nyren, O
    Bergstrom, R
    Ekbom, A
    Engholm, G
    Englund, A
    Glimelius, B
    [J]. CANCER CAUSES & CONTROL, 1998, 9 (01) : 49 - 56
  • [2] Agarwal B, 2002, J ACQ IMMUN DEF SYND, V29, P181, DOI 10.1097/00042560-200202010-00012
  • [3] [Anonymous], 2010, SEER CANC STAT REV 1
  • [4] NON-HODGKIN LYMPHOMAS IN OSAKA, JAPAN
    AOZASA, K
    TSUJIMOTO, M
    SAKURAI, M
    HONDA, M
    YAMASHITA, K
    HANADA, M
    SUGIMOTO, A
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (04): : 487 - &
  • [5] Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature
    Arora, Neeraj
    Manipadam, Marie Therese
    Nair, Sheila
    [J]. LEUKEMIA & LYMPHOMA, 2013, 54 (05) : 1004 - 1011
  • [6] Case-control Study of Risk Factors for Non-Hodgkin Lymphoma in Mumbai, India
    Balasubramaniam, Ganesh
    Saoba, Sushama
    Sarade, Monika
    Pinjare, Suvarna
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (02) : 775 - 780
  • [7] Lympho-hemopoietic malignancies in India
    Bhutani, M
    Vora, A
    Kumar, L
    Kochupillai, V
    [J]. MEDICAL ONCOLOGY, 2002, 19 (03) : 141 - 150
  • [8] Cancer risk in persons with HIV/AIDS in India: A review and future directions for research
    Biggar R.J.
    Chaturvedi A.K.
    Bhatia K.
    Mbulaiteye S.M.
    [J]. Infectious Agents and Cancer, 4 (1)
  • [9] The rise in incidence of lymphomas in Europe 1985-1992
    Cartwright, R
    Brincker, H
    Carli, PM
    Clayden, D
    Coebergh, JW
    Jack, A
    McNally, R
    Morgan, G
    de Sanjose, S
    Tumino, R
    Vornanen, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (04) : 627 - 633
  • [10] DEVESA SS, 1992, CANCER RES, V52, pS5432